CN-119506119-B - Lactobacillus paracasei W1 and application thereof in inhibiting clostridium difficile infection

Abstract

The invention discloses lactobacillus paracasei (Lacticaseibacillus paracasei) W1 and application thereof in inhibiting clostridium difficile (Clostridioides difficile) infection, and relates to the technical field of probiotics application. Lactobacillus paracasei W1 has the ability to tolerate low pH and high concentration of bile salts of the gastrointestinal tract, and its sterile fermentation supernatant can inhibit the growth of clostridium difficile and the formation of a biofilm. Animal experiments show that lactobacillus paracasei W1 can inhibit the colonization of clostridium difficile in vivo, improve the damage of colonic mucosa, relieve the shortening of colon and reduce the inflammation caused by clostridium difficile infection. The strain has wide application prospect in preparing medicines for inhibiting clostridium difficile infection.

Inventors

• TU ZENG
• TAN YU
• JIA QIANYING
• CUI YIHONG

Assignees

• 重庆医科大学
• 重庆医科大学附属第一医院

Dates

Publication Date

20260512

Application Date

20240905

Claims (5)

1. 1. The lactobacillus paracasei (Lacticaseibacillus paracasei) W1 is characterized in that the lactobacillus paracasei W1 is preserved in China Center for Type Culture Collection (CCTCC) No. M2024619.
2. 2. A Lactobacillus paracasei W1 according to claim 1, wherein the nucleotide sequence of 16S rRNA of the Lactobacillus paracasei W1 is shown in SEQ ID No. 1.
3. 3. Use of a strain of lactobacillus paracasei W1 as defined in claim 1 for the manufacture of a medicament for inhibiting clostridium difficile (c.
4. 4. Use of a strain of lactobacillus paracasei W1 according to claim 1 in a medicament for the prevention and/or treatment of colitis caused by clostridium difficile infection.
5. 5. The use of Lactobacillus paracasei W1 strain according to claim 4 for the preparation of a medicament for the prophylaxis and/or treatment of colitis caused by Clostridium difficile infection, wherein the Lactobacillus paracasei content of the medicament is not less than 1.0X10 9 CFU/mL or 1.0X10 9 CFU/g.

Description

Lactobacillus paracasei W1 and application thereof in inhibiting clostridium difficile infection Technical Field The invention relates to the technical field of microbial engineering, in particular to lactobacillus paracasei (Lacticaseibacillus paracasei) W1 and application thereof in inhibiting clostridium difficile (C. Difficilie) infection. Background Clostridium difficile (c. Difficilie) is a gram-positive anaerobic bacillus, a common pathogen for diarrhea in hospitalized patients. Clostridium difficile can form spores, and has strong tolerance to physical and chemical factors such as heat, drying, disinfectants and the like, so that the clostridium difficile can survive for a long time in the environment. Thus, spores are the dominant form of their spread among the population. Toxin a and toxin B are the main causative agents of clostridium difficile, both of which act on colonic epithelium and immune cells, inducing innate immunity and causing inflammatory responses. It is noted that toxin B may be a trigger for multiple organ dysfunction syndrome. Meanwhile, clostridium difficile can obtain antibiotic resistance through the modes of forming a biological film, carrying out plasmid transfer and the like, so that the treatment effect of the antibiotic is affected. Clostridium difficile infection (Clostridioides difficile infection, CDI) accounts for 30% of antibiotic associated diarrhea (Antibiotic-associated diarrhea, AAD). Clinical manifestations include mild to moderate diarrhea, pseudomembranous colitis, moderate toxic megacolon and even death. Currently, the treatment of Clostridium Difficile Infection (CDI) relies on antibiotics such as metronidazole, vancomycin and fidaxomicin, but fecal microorganism transplantation (Fecal microbiota transplantation, FMT) is increasingly becoming a more advantageous alternative to the treatment of recurrent CDI as bacterial resistance and risk of recurrence of CDI increase. FMT is intended to treat CDI by restoring diversity of intestinal microbiota, reconstructing intestinal mucosal barriers, and restoring metabolism of microbiota. Some studies have shown that FMT can not only treat colitis-related diseases, but also has potential application in the treatment of irritable bowel syndrome, depression and even cancer. Nonetheless, we should consider the potential risk of FMT. FMT treatment may have some uncertain relevance to certain diseases, including peripheral neuropathy, idiopathic thrombocytopenic purpura, sjogren's syndrome, and rheumatoid arthritis. Thus, there is a great clinical need for new highly safe treatments. With the increasing importance of probiotics in the treatment of colonic inflammation, the antibacterial activity of specific probiotics against clostridium difficile remains poorly understood. Studies have shown that the probiotic combination comprising lactobacillus acidophilus CL1285 and lactobacillus casei LBC80R is well tolerated and can effectively reduce the risk of diarrhea associated with antibiotics. Furthermore, one Meta analysis showed that lactobacillus casei is better and safer for preventing antibiotic-associated diarrhea than other lactobacillus. However, at present, no in-vivo or in-vitro study on inhibiting clostridium difficile by lactobacillus paracasei is available at home and abroad. Through the analysis, the prior art has the problems and the defects that at present, no probiotic medicine or pharmaceutical composition specially used for inhibiting clostridium difficile exists on the domestic market. Thus, there is a great potential for developing such lactic acid bacteria for reducing the extent of infection. Disclosure of Invention The invention aims to solve the problems and provide lactobacillus paracasei W1 and application thereof in inhibiting clostridium difficile infection, wherein the lactobacillus paracasei has the capability of tolerating low pH and high concentration bile salts in the gastrointestinal tract, the sterile supernatant can inhibit the growth and biofilm formation of clostridium difficile in vitro, the bacterium can effectively reduce the death rate of clostridium difficile infected mice in animal experiments, and the lactobacillus paracasei has good antibacterial effect on clostridium difficile in vitro and in vivo. In order to achieve the above purpose, the technical scheme of the invention is as follows: A lactobacillus paracasei (Lacticaseibacillus paracasei) W1 is characterized in that the preservation number of the lactobacillus paracasei is CCTCC No. M2024619. Further, the nucleotide sequence of the 16S rRNA of the lactobacillus paracasei W1 is shown as SEQ ID No. 1 Use of lactobacillus paracasei W1 for inhibiting clostridium difficile (c. Further, the lactobacillus paracasei W1 sterile supernatant inhibits clostridium difficile growth and biofilm formation. Use of lactobacillus paracasei W1 for the preparation of a medicament or pharmaceutical composition for the prevention and treatment of